Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients

NCT06800391 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Pseudomyxoma Peritonei

Interventions

COMBINATION_PRODUCT: Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano